Allergic Asthma

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 25 15 72
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Atopic Asthma, Susceptibility to 6
Ige-Mediated Allergic Asthma 72
Extrinsic Asthma 25
Asthma Allergic 55
Atopic Asthma 12


External Ids:

Disease Ontology 12 DOID:9415
ICD9CM 35 493.0
SNOMED-CT 68 16862005
ICD10 33 J45
UMLS 72 C0155877 C1827849

Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder. A hallmark of asthma is bronchial hyperresponsiveness, which means the airways are especially sensitive to irritants and respond excessively. Because of this hyperresponsiveness, attacks can be triggered by irritants other than allergens, such as physical activity, respiratory infections, or exposure to tobacco smoke, in people with allergic asthma. An asthma attack is characterized by tightening of the muscles around the airways (bronchoconstriction), which narrows the airway and makes breathing difficult. Additionally, the immune reaction can lead to swelling of the airways and overproduction of mucus. During an attack, an affected individual can experience chest tightness, wheezing, shortness of breath, and coughing. Over time, the muscles around the airways can become enlarged (hypertrophied), further narrowing the airways. Some people with allergic asthma have another allergic disorder, such as hay fever (allergic rhinitis) or food allergies. Asthma is sometimes part of a series of allergic disorders, referred to as the atopic march. Development of these conditions typically follows a pattern, beginning with eczema (atopic dermatitis), followed by food allergies, then hay fever, and finally asthma. However, not all individuals with asthma have progressed through the atopic march, and not all individuals with one allergic disease will develop others.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to aspergillosis and pollen allergy, and has symptoms including wheezing, coughing and chest tightness. An important gene associated with Allergic Asthma is MS4A2 (Membrane Spanning 4-Domains A2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Budesonide and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 32.8 IL5 IL4 IL10 IFNG CCL17
2 pollen allergy 31.5 RNASE3 IL5 IL4R IL13
3 intrinsic asthma 31.4 RNASE3 IL5 IL4
4 bronchitis 31.3 RNASE3 IL5 CCL11
5 hypereosinophilic syndrome 31.3 RNASE3 IL5 IL4 IL13 IGHE CCL17
6 rhinitis 31.2 RNASE3 IL5 IL4R IL4 IL13 IGHE
7 autoimmune disease 31.2 IL4 IL17A IL10 IFNG
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.2 IL17A IL10 IFNG
9 bacterial infectious disease 31.1 IL17A IL10 IFNG
10 status asthmaticus 31.0 RNASE3 IL5 CCL5
11 idiopathic interstitial pneumonia 31.0 IL4 IL13 IFNG
12 cytokine deficiency 31.0 IL9 IL5 IL13
13 allergic bronchopulmonary aspergillosis 30.9 IL5 IL4 CCL17
14 ige responsiveness, atopic 30.9 STAT6 RNASE3 MS4A2 IL9 IL5 IL4R
15 lung disease 30.9 RNASE3 IL5 IL17A IL13 IL10 CCL5
16 chlamydia 30.9 IL4 IL10 IFNG
17 immune deficiency disease 30.8 IL4 IL13 IL10
18 drug allergy 30.7 MS4A2 IL5 IL4R
19 respiratory syncytial virus infectious disease 30.7 IL5 IL13 CCL5
20 ascaris lumbricoides infection 30.7 TSLP IL5 IL13
21 parasitic protozoa infectious disease 30.6 IL4 IL10 IFNG
22 churg-strauss syndrome 30.6 RNASE3 IL5 IL10 CCL17
23 esophagitis, eosinophilic, 1 30.5 TSLP IL5 IL13 CCL11
24 esophagitis 30.5 TSLP IL5 IL13 CCL11
25 eosinophilic gastroenteritis 30.5 TSLP RNASE3 IL5 CCL11
26 pneumonia 30.4 IL5 IL13 IL10 CCL5 CCL11
27 pulmonary eosinophilia 30.4 RNASE3 IL5 IL4 IL13 CCL5 CCL17
28 latex allergy 30.4 RNASE3 IL5 IL4 IL13 IGHE
29 contact dermatitis 30.4 IL5 IL4 IL10 IFNG CCL17
30 allergic rhinitis 30.4 RNASE3 MS4A2 IL5 IL4R IL4 IL13
31 pulmonary tuberculosis 30.3 IL4 IL10 IFNG
32 common variable immunodeficiency 30.3 IL5 IL4 IL10 IFNG
33 gastrointestinal system disease 30.3 IL17A IL10 IFNG CCL11
34 mycobacterium tuberculosis 1 30.3 IL4 IL17A IL10 IFNG
35 colitis 30.3 IL4 IL17A IL10 IFNG
36 tetanus 30.3 IL5 IL4 IL13 IL10 IFNG
37 vernal keratoconjunctivitis 30.3 RNASE3 IL5 IL4 IL13 CCL5 CCL11
38 conjunctivitis 30.2 RNASE3 MS4A2 IL5 IL4 IL13 IFNG
39 allergic conjunctivitis 30.1 RNASE3 IL5 IL4 IL13 IFNG CCL11
40 pulmonary disease, chronic obstructive 30.0 RNASE3 IL17A IL13 CCL5 CCL11 ADAM33
41 allergic contact dermatitis 30.0 IL5 IL4 IL17A IL10 IFNG CCL17
42 proteasome-associated autoinflammatory syndrome 1 29.9 RNASE3 IL5 IL4 IL17A IL13 IL10
43 gastroenteritis 29.9 TSLP RNASE3 IL5 IL4 IL10 CCL11
44 common cold 29.9 TSLP RNASE3 IL5 IL13 CCL5 CCL11
45 inflammatory bowel disease 29.9 STAT6 IL4 IL17A IL13 IL10 IFNG
46 keratoconjunctivitis 29.9 RNASE3 IL5 IL4 IL13 IFNG CCL17
47 rheumatoid arthritis 29.9 IL4 IL17A IL10 IFNG CCL5
48 food allergy 29.9 STAT6 RNASE3 MS4A2 IL5 IL4 IL13
49 sarcoidosis 1 29.5 IL9 IL13 IFNG CCL17
50 schistosomiasis 29.3 STAT6 RNASE3 IL5 IL4 IL13 IL10

Graphical network of the top 20 diseases related to Allergic Asthma:

Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma


  • wheezing
  • coughing
  • chest tightness
  • shortness of breath
  • rapid breathing

MGI Mouse Phenotypes related to Allergic Asthma:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 CCL11 CCL17 CCL5 GATA3 IFNG IL10
2 immune system MP:0005387 10.19 CCL11 CCL17 CCL5 GATA3 IFNG IL10
3 digestive/alimentary MP:0005381 10.13 GATA3 IFNG IL10 IL13 IL17A IL4
4 homeostasis/metabolism MP:0005376 10.1 GATA3 IFNG IL10 IL13 IL17A IL4
5 endocrine/exocrine gland MP:0005379 10.06 GATA3 IFNG IL10 IL13 IL17A IL4
6 integument MP:0010771 9.76 GATA3 IFNG IL10 IL13 IL4 IL4R
7 no phenotypic analysis MP:0003012 9.5 ADAM33 GATA3 IFNG IL10 IL13 IL17A
8 respiratory system MP:0005388 9.36 CCL11 IFNG IL10 IL13 IL17A IL4

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Nitric Oxide Approved Phase 4 10102-43-9 145068
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Cetirizine Approved Phase 4 83881-51-0 2678
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Norepinephrine Approved Phase 4 51-41-2 439260
Terbutaline Approved Phase 4 23031-25-6 5403
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
Theophylline Approved Phase 4 58-55-9 2153
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Metronidazole Approved Phase 4 443-48-1 4173
Vancomycin Approved Phase 4 1404-90-6 441141 14969
Histamine Approved, Investigational Phase 4 51-45-6 774
Azelastine Approved Phase 4 58581-89-8 2267
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
25 Antibodies, Monoclonal Phase 4
26 Neurotransmitter Agents Phase 4
27 Adrenergic Agonists Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Adrenergic beta-2 Receptor Agonists Phase 4
30 Adrenergic Agents Phase 4
31 Platelet Aggregation Inhibitors Phase 4
32 Albuterol Phase 4
33 Tocolytic Agents Phase 4
34 Formoterol Fumarate Phase 4
35 Adrenergic alpha-Agonists Phase 4
36 Epinephryl borate Phase 4
37 Mydriatics Phase 4
38 Vasoconstrictor Agents Phase 4
39 Protective Agents Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Adjuvants, Immunologic Phase 4
42 Viscosupplements Phase 4
43 Gastrointestinal Agents Phase 4
44 Fibrinolytic Agents Phase 4
45 Antipyretics Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 Acidophilus Phase 4
Beclomethasone Phase 4 4419-39-0 20469
49 Prednisolone acetate Phase 4
50 Methylprednisolone Acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 332)
# Name Status NCT ID Phase Drugs
1 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
3 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
4 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
5 The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Completed NCT00657891 Phase 4 Omalizumab;Placebo
6 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab) on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
7 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00329381 Phase 4 Xolair;Xolair
8 A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
9 A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID Completed NCT00296530 Phase 4 fluticasone propionate/salmeterol;fluticasone propionate;montelukast
10 A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis Completed NCT00903227 Phase 4 Fluticasone Evohaler pMDI;Placebo;Fluticasone Evohaler;Placebo intranasal spray;fluticasone propionate (Flixonase®)
11 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
12 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
13 A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy Completed NCT00264849 Phase 4 Omalizumab
14 Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
15 Assessment of Bronchodilatory Effects of Cetirizine in Adults With Concomitant Allergic Rhinitis and Mild Asthma as Measured by Impulse Oscillometry. Completed NCT01781507 Phase 4 Cetirizine;Placebo
16 Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
17 A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
18 Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study. Completed NCT00518518 Phase 4 Staloral 300;placebo
19 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
20 A Randomized, Double-Blind Trial of the Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
21 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
22 A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
23 A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma Completed NCT00492076 Phase 4
24 Efficacy of Lactbacillus GG on Wheeze and Allergic Sensitization in Infants at Risk Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
25 Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
26 Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment. Completed NCT00454051 Phase 4 Omalizumab;placebo
27 A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
28 A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair) Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
29 A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT) Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
30 A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
31 Efficacy Of Nebulised Beclometasone Versus Placebo In Preventing Viral Wheezing In Pre-School Children Completed NCT01265342 Phase 4 Beclomethasone;Placebo
32 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20) Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
33 The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma Completed NCT00133042 Phase 4 omalizumab
34 Inner-City Anti-IgE Therapy for Asthma (ICAC-08) Completed NCT00377572 Phase 4
35 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
36 A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization Completed NCT00555971 Phase 4 Omalizumab;placebo
37 A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis Completed NCT01550471 Phase 4 Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo;Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase;QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo;QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris;Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase;Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
38 Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations Completed NCT01865500 Phase 4 Budesonide 4 mg;Budesonide 8 mg;Metil prednisolone
39 Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation After Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients Recruiting NCT03051698 Phase 4 C1-inhibitor;Antibiotics
40 Role of Montelukast in Asthma and Allergic Rhinitis Patients Not yet recruiting NCT03380975 Phase 4 Montelukast 10mg
41 Proof of Concept Study to Assess Downstream Effects of Using Combined Intranasal Fluticasone Propionate Plus Azelastine Nasal Spray on Asthmatic Inflammation in Patients With Persistent Asthma and Allergic Rhinitis Terminated NCT02953106 Phase 4 Azelastine-Fluticasone Nasal;Placebos
42 A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma Withdrawn NCT00242359 Phase 4 omalizumab
43 Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
44 The Efficacy of Mepolizumab Treatment on Rhinovirus Induced Asthma Exacerbations Unknown status NCT01520051 Phase 3 Mepolizumab;Placebo
45 The Effect of a Humanised Monoclonal Anti-IgE Antibody,Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-atpic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
46 Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial Completed NCT02552667 Phase 3 HCP1102+HGP0711Placebo;HCP1102Placebo+HGP0711
47 A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study Completed NCT00109200 Phase 3 Xolair (omalizumab)
48 A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma Completed NCT00079937 Phase 3 Omalizumab;Placebo;Fluticasone
49 An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study Completed NCT00482248 Phase 3 Omalizumab
50 An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment Completed NCT01328886 Phase 3 Omalizumab

Search NIH Clinical Center for Allergic Asthma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

Lung, T Cells, Testes, Smooth Muscle, Skin, Neutrophil, B Cells

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 6758)
# Title Authors PMID Year
Association between nasal allergy and a coding variant of the Fc epsilon RI beta gene Glu237Gly in a Japanese population. 71
11702205 2001
Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. 71
8842731 1996
A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. 71
8817330 1996
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 9 38
20483734 2010
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. 9 38
20458139 2010
Regulatory T cells in many flavors control asthma. 9 38
20164832 2010
Ligand-based molecular design of 4-benzylpiperidinealkylureas and amides as CCR3 antagonists. 9 38
19960358 2010
Itk inhibitors: a patent review. 9 38
20218931 2010
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. 9 38
19945799 2010
Allergic asthma in patients with common variable immunodeficiency. 9 38
19839975 2010
IL-13 Gene Polymorphisms are Associated With Rhinosinusitis and Eosinophilic Inflammation in Aspirin Intolerant Asthma. 9 38
20358028 2010
TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway. 9 38
20230634 2010
Effects of functional relaxation and guided imagery on IgE in dust-mite allergic adult asthmatics: a randomized, controlled clinical trial. 9 38
20145487 2010
Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. 9 38
20128689 2010
Activation of signal transducer and activator of transcription factor 1 by interleukins-13 and -4 in cultured human bronchial smooth muscle cells. 9 38
20093796 2009
A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E2 pathway. 9 38
19552640 2009
Development of allergen-induced airway inflammation in the absence of T-bet regulation is dependent on IL-17. 9 38
19783683 2009
Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE. 9 38
19359220 2009
Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma. 9 38
19217272 2009
Relationship between exhaled nitric oxide and IgE sensitisation in patients with asthma: influence of steroid treatment. 9 38
20298397 2009
Pulmonary suppressor of cytokine signaling-1 induced by IL-13 regulates allergic asthma phenotype. 9 38
19299500 2009
Soluble human leucocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. 9 38
19302248 2009
Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children. 9 38
19493463 2009
N-acetyltransferase 2 (NAT2) polymorphism in patients with atopic asthma. 9 38
19608015 2009
T-box 21 transcription factor is responsible for distorted T(H)2 differentiation in human peripheral CD4+ T cells. 9 38
19348920 2009
A TLR2 polymorphism is associated with type 1 diabetes and allergic asthma. 9 38
19148143 2009
Soluble interleukin-10 and transforming growth factor-beta in children with acute exacerbation of allergic asthma. 9 38
19191132 2009
CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. 9 38
19064280 2009
Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. 9 38
19188585 2009
Are genes associated with energy metabolism important in asthma and BMI? 9 38
19191138 2009
Nerve growth factor localization in the nasal mucosa of patients with persistent allergic rhinitis. 9 38
19076929 2009
Changes in RANTES and beta-thromboglobulin after intensive exercise in patients with allergic asthma. 9 38
18716401 2009
ITK inhibitors in inflammation and immune-mediated disorders. 9 38
19689375 2009
Foxp3 expressing regulatory T-cells in allergic disease. 9 38
20429425 2009
Activation of peripheral Th17 lymphocytes in patients with asthma. 9 38
19811428 2009
Association of HLA class II alleles with childhood asthma and Total IgE levels. 9 38
19052351 2008
IFN-gamma, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13. 9 38
19116009 2008
Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia. 9 38
18266831 2008
Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. 9 38
18926061 2008
Association of ADAM33 gene polymorphisms with adult allergic asthma and rhinitis in a Chinese Han population. 9 38
18778489 2008
Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo. 9 38
18694590 2008
Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. 9 38
18768888 2008
Genetic variation in immune signaling genes differentially expressed in asthmatic lung tissues. 9 38
18774388 2008
Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. 9 38
18691065 2008
MAP kinases mediate interleukin-13 effects on calcium signaling in human airway smooth muscle cells. 9 38
18441092 2008
Characterization of Der p 21, a new important allergen derived from the gut of house dust mites. 9 38
18445190 2008
Protective role of nuclear factor of activated T cells 2 in CD8+ long-lived memory T cells in an allergy model. 9 38
18329088 2008
Regulation of the high affinity IgE receptor (Fc epsilonRI) in human neutrophils: role of seasonal allergen exposure and Th-2 cytokines. 9 38
18382690 2008
Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. 9 38
18266877 2008
SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. 9 38
18053009 2008

Variations for Allergic Asthma

ClinVar genetic disease variations for Allergic Asthma:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MS4A2 NM_000139.5(MS4A2): c.710A> G (p.Glu237Gly) single nucleotide variant risk factor rs569108 11:59863104-59863104 11:60095631-60095631

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.88 STAT6 IL9 IL5 IL4R IL4 IL17A
Show member pathways
13.75 TSLP IL9 IL5 IL4R IL4 IL17A
Show member pathways
13.61 STAT6 IL9 IL5 IL4R IL4 IL17A
Show member pathways
13.48 STAT6 ITK IL9 IL5 IL4R IL4
Show member pathways
13.43 STAT6 IL9 IL5 IL4R IL4 IL17A
Show member pathways
13.38 IL9 IL5 IL4R IL4 IL17A IL13
Show member pathways
9 12.86 STAT6 IL5 IL4R IL4 IL13 IFNG
Show member pathways
12.73 MS4A2 ITK IL4R IL4 IL10 IGHE
Show member pathways
12.72 STAT6 IL5 IL4R IL4 IL17A IL13
12 12.68 STAT6 ITK IL4 IL17A IL10 IFNG
Show member pathways
12.68 ITK IL9 IL5 IL4 IL17A IL10
Show member pathways
12.66 MS4A2 ITK IL5 IL4 IL13 IGHE
Show member pathways
Show member pathways
Show member pathways
12.46 IL5 IL4 IL17A IL13 IFNG CCL17
Show member pathways
12.37 IL9 IL5 IL4 IL17A IL13 IL10
Show member pathways
12.16 IL9 IL5 IL4R IL4 IL17A IL13
Show member pathways
12.09 IL17A IL10 IFNG GATA3
21 12.02 IL5 IL4 IL10 IFNG
22 11.97 STAT6 IL4R IL4 IL17A IL13 IL10
23 11.93 IL5 IL4 IL13 IFNG GATA3
24 11.91 STAT6 IL4R IL10 IFNG
25 11.85 IL5 IL4R IL4
Show member pathways
11.84 IL5 IL4 IFNG GATA3
27 11.83 IL17A IFNG CCL5
28 11.82 IL4 IL17A IL13 IL10 IFNG CCL5
29 11.8 IL5 IL4 IL13 CCL5 CCL11
30 11.74 IL5 IL10 GATA3
31 11.72 STAT6 IL5 IL4R IL4 IL10 IGHE
32 11.64 IL4 IL13 IL10 CCL5
33 11.52 TSLP STAT6 CCL11
34 11.51 TSLP IL9 IL5 IL4 IL17A IL13
35 11.46 IL5 IL4R IL4 IFNG
36 11.41 IL5 IL4 IL13 IL10 IFNG
37 11.37 IL9 IL5 IL4 IL13 IL10 IFNG
38 11.34 IL9 IL5 IL4 IL17A IL13 IL10
39 11.26 TSLP IL9 IL5 IL4 IL17A IL13
40 11.13 IL9 IL5 IL4 IL17A IL13 IL10
41 11.03 STAT6 IL9 IL5 IL4R IL4 IL13

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TSLP RNASE3 IL9 IL5 IL4R IL4
2 extracellular space GO:0005615 9.44 TSLP RNASE3 IL9 IL5 IL4R IL4

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cellular response to tumor necrosis factor GO:0071356 9.84 GATA3 CCL5 CCL17 CCL11
2 cellular response to interferon-gamma GO:0071346 9.81 CCL5 CCL17 CCL11
3 neutrophil chemotaxis GO:0030593 9.81 CCL5 CCL17 CCL11
4 inflammatory response GO:0006954 9.81 MS4A2 IL9 IL5 IL17A IL13 IL10
5 chemokine-mediated signaling pathway GO:0070098 9.8 CCL5 CCL17 CCL11
6 response to virus GO:0009615 9.78 IFNG GATA3 CCL5 CCL11
7 monocyte chemotaxis GO:0002548 9.76 CCL5 CCL17 CCL11
8 positive regulation of cold-induced thermogenesis GO:0120162 9.76 STAT6 IL4R IL4 IL13
9 cellular response to interleukin-1 GO:0071347 9.73 IL17A CCL5 CCL17 CCL11
10 positive regulation of B cell proliferation GO:0030890 9.72 IL5 IL4 IL13
11 lymphocyte chemotaxis GO:0048247 9.7 CCL5 CCL17 CCL11
12 cytokine-mediated signaling pathway GO:0019221 9.7 STAT6 IL5 IL4R IL4 IL17A IL13
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 TSLP IL4 IL13 IFNG CCL5
14 positive regulation of mast cell degranulation GO:0043306 9.62 IL4R IL13
15 positive regulation of interleukin-5 production GO:0032754 9.62 TSLP GATA3
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 IL4 IL13 IL10 GATA3
17 positive regulation of immunoglobulin production GO:0002639 9.61 IL4R IL13
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL4 IL10
19 positive regulation of interleukin-5 secretion GO:2000664 9.6 TSLP GATA3
20 positive regulation of interleukin-23 production GO:0032747 9.59 IL17A IFNG
21 type 2 immune response GO:0042092 9.58 IL4 IL10
22 positive regulation of macrophage activation GO:0043032 9.58 IL4R IL13 IL10
23 regulation of isotype switching GO:0045191 9.57 IL4 IL10
24 interleukin-4-mediated signaling pathway GO:0035771 9.56 STAT6 IL4R
25 positive regulation of interleukin-13 production GO:0032736 9.54 TSLP IL4 GATA3
26 positive regulation of isotype switching to IgE isotypes GO:0048295 9.51 STAT6 IL4
27 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL4 IL13
28 immune response GO:0006955 9.44 MS4A2 IL9 IL5 IL4R IL4 IL17A

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 IL9 IL5 IL4 IL10
2 chemokine activity GO:0008009 9.54 CCL5 CCL17 CCL11
3 CCR chemokine receptor binding GO:0048020 9.43 CCL5 CCL17 CCL11
4 cytokine activity GO:0005125 9.36 TSLP IL9 IL5 IL4 IL17A IL13
5 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
6 CCR4 chemokine receptor binding GO:0031729 8.96 CCL5 CCL17

Sources for Allergic Asthma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....